PF4 and COVID-19: Interestingly, we also detected the presence of anti-β2-GPI/PF4 antibodies in all 3 patients with VITT, but not in patients with COVID-19, including those with thrombophilic complications, suggesting that the thrombotic mechanism underlying VITT is different from that of COVID-19 infection.